Payment overview · 2025
General Payments
$238.65
12 reported records · 7 companies
Healthcare provider profile · identity verified
Evan Michael Johnson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SARDIS CITY, AL · NPI 1659399772
Verified facts
What the public records show
CMS Open Payments records show Evan Michael Johnson, D.O. received $238.65 in general payments during 2025 across 12 reported records.
GlaxoSmithKline, LLC. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Shingrix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.27 | 20.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $44.72 | 18.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $43.54 | 18.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $37.80 | 15.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $27.51 | 11.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.81 | 7.9% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $18.00 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $238.65 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $48.27 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $48.27 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $43.54 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $37.80 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $29.22 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $29.22 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $27.51 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $15.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 41 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 131 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
131 | 89 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 511 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 450 | 149 |
| Gabapentin | Gabapentin | 336 | 76 |
| Clonazepam | Clonazepam | 305 | 45 |
| Zolpidem Tartrate | Zolpidem Tartrate | 301 | 46 |
| Omeprazole | Omeprazole | 295 | 95 |
| Pravastatin Sodium | Pravastatin Sodium | 284 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 73 |
| Losartan Potassium | Losartan Potassium | 218 | 66 |
| Metformin Hcl | Metformin Hcl | 206 | 71 |
| Amlodipine Besylate | Amlodipine Besylate | 199 | 68 |
| Simvastatin | Simvastatin | 189 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 61 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 166 | 28 |
| Celecoxib | Celecoxib | 164 | 57 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 51 |
| Trazodone Hcl | Trazodone Hcl | 149 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 144 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 43 |
| Alprazolam | Alprazolam | 142 | 25 |
| Tramadol Hcl | Tramadol Hcl | 141 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 131 | 89 |
| Ezetimibe | Ezetimibe | 129 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 128 | 33 |
| Meloxicam | Meloxicam | 118 | 38 |
| Lisinopril | Lisinopril | 115 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 44 |
| Januvia | Sitagliptin Phosphate | 100 | 20 |
| Lorazepam | Lorazepam | 98 | 12 |
| Jardiance | Empagliflozin | 97 | 19 |
| Buspirone Hcl | Buspirone Hcl | 96 | 20 |
| Montelukast Sodium | Montelukast Sodium | 95 | 32 |
| Donepezil Hcl | Donepezil Hcl | 90 | 23 |
| Sertraline Hcl | Sertraline Hcl | 86 | 23 |
| Carvedilol | Carvedilol | 85 | 26 |
| Eliquis | Apixaban | 85 | 16 |
| Potassium Chloride | Potassium Chloride | 82 | 26 |
| Temazepam | Temazepam | 80 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 26 |
| Mounjaro | Tirzepatide | 76 | 24 |
| Pregabalin | Pregabalin | 76 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 19 |
| Ozempic | Semaglutide | 69 | 16 |
| Raloxifene Hcl | Raloxifene Hcl | 69 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 26 |
| Synthroid | Levothyroxine Sodium | 66 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 64 | 21 |
| Azithromycin | Azithromycin | 63 | 60 |
| Memantine Hcl | Memantine Hcl | 59 | 14 |
| Famotidine | Famotidine | 58 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 22 |
| Furosemide | Furosemide | 54 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 19 |
| Allopurinol | Allopurinol | 52 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 52 | 18 |
| Prednisone | Prednisone | 52 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 52 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 47 | 13 |
| Farxiga | Dapagliflozin Propanediol | 42 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 41 |
| Cefdinir | Cefdinir | 41 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | 13 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 40 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 18 |
| Lovastatin | Lovastatin | 38 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Irbesartan | Irbesartan | 36 | 12 |
| Ramipril | Ramipril | 36 | suppressed |
| Fenofibrate | Fenofibrate | 35 | 11 |
| Valsartan | Valsartan | 35 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | 11 |
| Metformin Hcl Er | Metformin Hcl | 31 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 31 | 11 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Glimepiride | Glimepiride | 28 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | 13 |
| Rybelsus | Semaglutide | 27 | suppressed |
| Zaleplon | Zaleplon | 27 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 23 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Silodosin | Silodosin | 23 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 22 | 20 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 21 | suppressed |
| Fluconazole | Fluconazole | 20 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 15 | 15 |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Armodafinil | Armodafinil | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | 11 |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $238.65 · 12 records | GlaxoSmithKline, LLC. | AREXVY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, GEMTESA, Kerendia, OTEZLA, REPATHA, SHINGRIX | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error